Dawn Kleindorfer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Dawn Kleindorfer has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Brett M. Kissela
Department of Neurology and Rehabilitation Medicine, University of Cincinnati, OH
18 shared publications Daniel Woo
University of Cincinnati, Cincinnati, OH
15 shared publicationsJane Khoury
Cincinnati Children’s Hosp Med Cntr, Cincinnati, OH
12 shared publicationsKathleen Alwell
University of Cincinnati, Cincinnati, OH
12 shared publicationsCharles J. Moomaw
University of Cincinnati, Cincinnati, OH
11 shared publicationsJoseph P. Broderick
From the Department of Neurology, Ohio Health Methodist Riverside Hospital, Columbus (B.S.K.); Department of Emergency Medicine, Division of Neurocritical Care (O.A.), UC Department Neurology/Rehabilitation (J.P.B., P.K., K.S.A., C.J.M., B.M.K., M.L.F., D.W., S.F., D.O.K.), and Department of Emergency Medicine (J.M.), University of Cincinnati, Ohio; Department of Biostatistics and Epidemiology, Cincinnati Children’s Hospital Medical Center, Ohio (H.S.); Department of Geography and Planning,...
10 shared publications
Latest Publications
- 14 March 2019
- Published by Wolters Kluwer Health in American Journal of Medical Quality
- Vol. 34 (6) , 585-589
Stroke Center Certification Is Associated With Improved Guideline Concordance
Measurement of quality of stroke care has become increasingly important, but data come mostly from programs in hospitals that choose to participate in certification programs, which may not be representative of the care provided in nonparticipating hospitals. The authors sought to determine differences in quality of care metric concordance for acute ischemic stroke among hospitals designated as a primary stroke center, comprehensive stroke center, and non-stroke center in a population-based epidemiologic study. Significant differences were found in both patient demographics and in concordance with guideline-based quality metrics. These differences may help inform quality improvement efforts across hospitals involved in certification as well as those that are not.
- 14 March 2019
- Published by Wolters Kluwer Health in American Journal of Medical Quality
- Vol. 34 (6) , 585-589
Stroke Center Certification Is Associated With Improved Guideline Concordance
Measurement of quality of stroke care has become increasingly important, but data come mostly from programs in hospitals that choose to participate in certification programs, which may not be representative of the care provided in nonparticipating hospitals. The authors sought to determine differences in quality of care metric concordance for acute ischemic stroke among hospitals designated as a primary stroke center, comprehensive stroke center, and non-stroke center in a population-based epidemiologic study. Significant differences were found in both patient demographics and in concordance with guideline-based quality metrics. These differences may help inform quality improvement efforts across hospitals involved in certification as well as those that are not.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract 82: Endovascular Therapy Eligibility in the Advent of DAWN and DEFUSE-3 Results
Introduction: We previously estimated that, among 2297 ischemic stroke patients in our 1.3 million metropolitan population in 2010, 159 were potentially IV rtPA (IVT)- and 29 were endovascular (EVT)-eligible based on AHA Class I, Level A guideline criteria; this projected to 31,000 IVT and 5600 EVT-eligible patients in the US annually. Given recent DAWN and DEFUSE 3 results suggesting EVT benefit beyond 6 hours to 24 hours, we aim to estimate the number of additional EVT-eligible patients in our region. Methods: We ascertained all hospitalized AIS patients ≥18 years old in 2010 using ICD-9 codes 430-436 within Greater Cincinnati/Northern Kentucky (GCNK) population; all cases were physician-reviewed. GCNK patients were considered potentially DAWN-eligible if ≥18 years, presenting within 5 to 23 hours from onset, and with a baseline NIHSS ≥10, prestroke mRS 0-1, platelets ≥50k, glucose 51-399 mg/dL, INR ≤3.0 and creatinine ≤3.0. Based on single-center (Pittsburgh) data, an eligibility proportion of 22% for both large vessel occlusion (LVO) and clinical-imaging-mismatch (CIM) was then applied. Additional patients eligible by only DEFUSE 3 criteria were identified within the GCNK population by including NIHSS 6-9, prestroke mRS 2, and an upper age of 90 years among patients presenting within 5 to 15 hours. Based on single-center (Bern) data, LVO rates by NIHSS score were applied. Based on DEFUSE 3 screening estimates, a 50% target mismatch (TTM) rate was then applied. Results: Among 2297 ischemic stroke patients hospitalized in our region, 34 were potentially DAWN-eligible, including 8 estimated to meet LVO and CIM criteria, and 19 additional patients were DEFUSE 3-eligible, including 4 estimated to meet LVO and TMM criteria. Conclusion: The 6-24 hour EVT treatment window may increase EVT eligibility by approximately 40% in the GCNK metropolitan region annually, although this estimate is limited by small sample sizes and inferences. Estimates will be updated as further data become available by the time of presentation of this
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract 82: Endovascular Therapy Eligibility in the Advent of DAWN and DEFUSE-3 Results
Introduction: We previously estimated that, among 2297 ischemic stroke patients in our 1.3 million metropolitan population in 2010, 159 were potentially IV rtPA (IVT)- and 29 were endovascular (EVT)-eligible based on AHA Class I, Level A guideline criteria; this projected to 31,000 IVT and 5600 EVT-eligible patients in the US annually. Given recent DAWN and DEFUSE 3 results suggesting EVT benefit beyond 6 hours to 24 hours, we aim to estimate the number of additional EVT-eligible patients in our region. Methods: We ascertained all hospitalized AIS patients ≥18 years old in 2010 using ICD-9 codes 430-436 within Greater Cincinnati/Northern Kentucky (GCNK) population; all cases were physician-reviewed. GCNK patients were considered potentially DAWN-eligible if ≥18 years, presenting within 5 to 23 hours from onset, and with a baseline NIHSS ≥10, prestroke mRS 0-1, platelets ≥50k, glucose 51-399 mg/dL, INR ≤3.0 and creatinine ≤3.0. Based on single-center (Pittsburgh) data, an eligibility proportion of 22% for both large vessel occlusion (LVO) and clinical-imaging-mismatch (CIM) was then applied. Additional patients eligible by only DEFUSE 3 criteria were identified within the GCNK population by including NIHSS 6-9, prestroke mRS 2, and an upper age of 90 years among patients presenting within 5 to 15 hours. Based on single-center (Bern) data, LVO rates by NIHSS score were applied. Based on DEFUSE 3 screening estimates, a 50% target mismatch (TTM) rate was then applied. Results: Among 2297 ischemic stroke patients hospitalized in our region, 34 were potentially DAWN-eligible, including 8 estimated to meet LVO and CIM criteria, and 19 additional patients were DEFUSE 3-eligible, including 4 estimated to meet LVO and TMM criteria. Conclusion: The 6-24 hour EVT treatment window may increase EVT eligibility by approximately 40% in the GCNK metropolitan region annually, although this estimate is limited by small sample sizes and inferences. Estimates will be updated as further data become available by the time of presentation of this
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract WP327: CHADSVASC and HASBED Scores in Patients With Intracerebral Hemorrhage and Atrial Fibrillation
Background: Patients with intracerebral hemorrhage (ICH) and atrial fibrillation (a-fib) are at risk for having future ischemic events after stopping anticoagulation. Risk calculators (CHA 2 DS 2 -VASc and HAS-BLED) have been validated to assess risk for ischemic stroke and for major bleeding in a-fib patients. We sought to compare the distribution of these scores among ICH patients with a-fib within a large biracial population. Methods: The Genetic and Environmental Risk Factors for Hemorrhagic Stroke (GERFHS III) Study included a population-based retrospective chart review of spontaneous ICH among residents of the five-county Greater Cincinnati/Northern Kentucky region between 7/2008 and 12/2012. CHA 2 DS 2 -VASc (risk of ischemic stroke) and HAS-BED (risk of bleeding with anticoagulation; minus “L” because “labile INR” was unavailable) scores were calculated for all ICH patients with a-fib who survived the hospital stay. Published risk coefficients for each score were used to calculate predicted ischemic and bleeding events within one year of onset. Results: Among 1186 cases of spontaneous ICH, 232 had a-fib, of which 123 patients were excluded due to inpatient death or discharge to hospice. Among the remaining 109 cases, 7-8 would be expected to have a major bleeding event (on anticoagulation), and about 6 patients would be expected to have an ischemic stroke within one year (off anticoagulation), with 73 of the 109 patients having higher risk for major bleeding than for ischemic stroke. The correlation between the two scores was weak (Spearman r=.220, p=.021). Discussion: Comparison of CHA 2 DS 2 -VASc and HAS-BED scores suggest a higher CHA 2 DS 2 -VASc threshold for considering anticoagulation is needed for ICH a-fib patients to balance their higher risk of major bleeding. Further evaluation of the consequences of ischemic stroke and major bleeding would be needed to better understand the best treatment strategies for our patients.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract WP327: CHADSVASC and HASBED Scores in Patients With Intracerebral Hemorrhage and Atrial Fibrillation
Background: Patients with intracerebral hemorrhage (ICH) and atrial fibrillation (a-fib) are at risk for having future ischemic events after stopping anticoagulation. Risk calculators (CHA 2 DS 2 -VASc and HAS-BLED) have been validated to assess risk for ischemic stroke and for major bleeding in a-fib patients. We sought to compare the distribution of these scores among ICH patients with a-fib within a large biracial population. Methods: The Genetic and Environmental Risk Factors for Hemorrhagic Stroke (GERFHS III) Study included a population-based retrospective chart review of spontaneous ICH among residents of the five-county Greater Cincinnati/Northern Kentucky region between 7/2008 and 12/2012. CHA 2 DS 2 -VASc (risk of ischemic stroke) and HAS-BED (risk of bleeding with anticoagulation; minus “L” because “labile INR” was unavailable) scores were calculated for all ICH patients with a-fib who survived the hospital stay. Published risk coefficients for each score were used to calculate predicted ischemic and bleeding events within one year of onset. Results: Among 1186 cases of spontaneous ICH, 232 had a-fib, of which 123 patients were excluded due to inpatient death or discharge to hospice. Among the remaining 109 cases, 7-8 would be expected to have a major bleeding event (on anticoagulation), and about 6 patients would be expected to have an ischemic stroke within one year (off anticoagulation), with 73 of the 109 patients having higher risk for major bleeding than for ischemic stroke. The correlation between the two scores was weak (Spearman r=.220, p=.021). Discussion: Comparison of CHA 2 DS 2 -VASc and HAS-BED scores suggest a higher CHA 2 DS 2 -VASc threshold for considering anticoagulation is needed for ICH a-fib patients to balance their higher risk of major bleeding. Further evaluation of the consequences of ischemic stroke and major bleeding would be needed to better understand the best treatment strategies for our patients.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract WP50: Potential Impact of Triage Using Non-Contrast Head CT and Stroke Severity on a Regional Stroke System of Care: A Population-Based Study
Background and Purpose: Acute ischemic stroke (AIS) patients may benefit from endovascular therapy (EVT) up to 24 hours since last known normal (LKN). Advanced imaging, including CT or MR angiography and perfusion studies, is required for patient selection. Large non-thrombectomy centers may be able to obtain and interpret these images quickly, but smaller hospitals may not have sufficient real-time CT technician and radiology support. We estimated transfer rates using non-contrast head CT and stroke severity to select patients to be transferred to larger centers for evaluation. Methods: We identified all AIS among residents of the Greater Cincinnati/Northern Kentucky Stroke Study region in 2010 comprising approximately 1.3 million people. Study nurses abstracted relevant information from the medical record, including times of symptom onset, LKN, and ED arrival, and all cases were verified by study physicians. Only cases age ≥18 with baseline mRS 0-2 that presented to an ED were included. Among cases that presented between 6 and 24 hours from LKN, those without evidence of acute infarct on head CT and with initial NIHSS ≥6 or ≥10 were identified. Results: Of 1359 AIS cases at local EDs, 448 (33.0%) presented between 6 and 24 hours, of which s383 (85.5%) showed no evidence of acute infarct on CT. Of cases with no acute infarct on CT, 89/383 (23.2%) had NIHSS ≥6, of which 66 (74.2%) initially presented to a hospital without thrombectomy capabilities; and 51/383 (13.3%) had NIHSS ≥10, of which 40 (78.4%) presented to a non-thrombectomy hospital. Conclusions: From 6 to 24 hours after stroke onset within our population, 40-66 AIS patients annually (0.8-1.3/week, or 3-5 patients per 100,000 persons per year) may present to non-thrombectomy hospitals and need to be transferred using non-contrast CT and stroke severity as screening tools. Such an approach may sufficiently mitigate the impact of delays in treatment on outcomes, without overburdening the referring nor accepting hospitals.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract WP50: Potential Impact of Triage Using Non-Contrast Head CT and Stroke Severity on a Regional Stroke System of Care: A Population-Based Study
Background and Purpose: Acute ischemic stroke (AIS) patients may benefit from endovascular therapy (EVT) up to 24 hours since last known normal (LKN). Advanced imaging, including CT or MR angiography and perfusion studies, is required for patient selection. Large non-thrombectomy centers may be able to obtain and interpret these images quickly, but smaller hospitals may not have sufficient real-time CT technician and radiology support. We estimated transfer rates using non-contrast head CT and stroke severity to select patients to be transferred to larger centers for evaluation. Methods: We identified all AIS among residents of the Greater Cincinnati/Northern Kentucky Stroke Study region in 2010 comprising approximately 1.3 million people. Study nurses abstracted relevant information from the medical record, including times of symptom onset, LKN, and ED arrival, and all cases were verified by study physicians. Only cases age ≥18 with baseline mRS 0-2 that presented to an ED were included. Among cases that presented between 6 and 24 hours from LKN, those without evidence of acute infarct on head CT and with initial NIHSS ≥6 or ≥10 were identified. Results: Of 1359 AIS cases at local EDs, 448 (33.0%) presented between 6 and 24 hours, of which s383 (85.5%) showed no evidence of acute infarct on CT. Of cases with no acute infarct on CT, 89/383 (23.2%) had NIHSS ≥6, of which 66 (74.2%) initially presented to a hospital without thrombectomy capabilities; and 51/383 (13.3%) had NIHSS ≥10, of which 40 (78.4%) presented to a non-thrombectomy hospital. Conclusions: From 6 to 24 hours after stroke onset within our population, 40-66 AIS patients annually (0.8-1.3/week, or 3-5 patients per 100,000 persons per year) may present to non-thrombectomy hospitals and need to be transferred using non-contrast CT and stroke severity as screening tools. Such an approach may sufficiently mitigate the impact of delays in treatment on outcomes, without overburdening the referring nor accepting hospitals.
- 1 August 2017
- Published by Wolters Kluwer Health in Stroke
- Vol. 48 (8) , 2164-2170
Estimated Impact of Emergency Medical Service Triage of Stroke Patients on Comprehensive Stroke Centers
Background and Purpose—: The American Stroke Association recommends that Emergency Medical Service bypass acute stroke–ready hospital (ASRH)/primary stroke center (PSC) for comprehensive stroke centers (CSCs) when transporting appropriate stroke patients, if the additional travel time is ≤15 minutes. However, data on additional transport time and the effect on hospital census remain unknown. Methods—: Stroke patients ≥20 years old who were transported from home to an ASRH/PSC or CSC via Emergency Medical Service in 2010 were identified in the Greater Cincinnati area population of 1.3 million. Addresses of all patients’ residences and hospitals were geocoded, and estimated travel times were calculated. We estimated the mean differences between the travel time for patients taken to an ASRH/PSC and the theoretical time had they been transported directly to the region’s CSC. Results—: Of 929 patients with geocoded addresses, 806 were transported via Emergency Medical Service directly to an ASRH/PSC. Mean additional travel time of direct transport to the CSC, compared with transport to an ASRH/PSC, was 7.9±6.8 minutes; 85% would have ≤15 minutes added transport time. Triage of all stroke patients to the CSC would have added 727 patients to the CSC’s census in 2010. Limiting triage to the CSC to patients with National Institutes of Health Stroke Scale score of ≥10 within 6 hours of onset would have added 116 patients (2.2 per week) to the CSC’s annual census. Conclusions—: Emergency Medical Service triage to CSCs based on stroke severity and symptom duration may be feasible. The impact on stroke systems of care and patient outcomes remains to be determined and requires prospective evaluation.
- 1 August 2017
- Published by Wolters Kluwer Health in Stroke
- Vol. 48 (8) , 2164-2170
Estimated Impact of Emergency Medical Service Triage of Stroke Patients on Comprehensive Stroke Centers
Background and Purpose—: The American Stroke Association recommends that Emergency Medical Service bypass acute stroke–ready hospital (ASRH)/primary stroke center (PSC) for comprehensive stroke centers (CSCs) when transporting appropriate stroke patients, if the additional travel time is ≤15 minutes. However, data on additional transport time and the effect on hospital census remain unknown. Methods—: Stroke patients ≥20 years old who were transported from home to an ASRH/PSC or CSC via Emergency Medical Service in 2010 were identified in the Greater Cincinnati area population of 1.3 million. Addresses of all patients’ residences and hospitals were geocoded, and estimated travel times were calculated. We estimated the mean differences between the travel time for patients taken to an ASRH/PSC and the theoretical time had they been transported directly to the region’s CSC. Results—: Of 929 patients with geocoded addresses, 806 were transported via Emergency Medical Service directly to an ASRH/PSC. Mean additional travel time of direct transport to the CSC, compared with transport to an ASRH/PSC, was 7.9±6.8 minutes; 85% would have ≤15 minutes added transport time. Triage of all stroke patients to the CSC would have added 727 patients to the CSC’s census in 2010. Limiting triage to the CSC to patients with National Institutes of Health Stroke Scale score of ≥10 within 6 hours of onset would have added 116 patients (2.2 per week) to the CSC’s annual census. Conclusions—: Emergency Medical Service triage to CSCs based on stroke severity and symptom duration may be feasible. The impact on stroke systems of care and patient outcomes remains to be determined and requires prospective evaluation.
- 1 July 2017
- Published by Wolters Kluwer Health in Stroke
- Vol. 48 (7) , 2000-2002
Cost of Alteplase Has More Than Doubled Over the Past Decade
Background and Purpose—: Intravenous alteplase (tissue-type plasminogen activator) has been shown to be cost-effective because of savings in long-term disability. In October of 2005, an increased DRG payment to hospitals for alteplase-treated stroke patients was introduced. We sought to describe the trends in the cost of alteplase over time, in comparison to trends in hospital reimbursement in the United States. Methods—: Using publicly available information on the Centers for Medicare and Medicaid Services (CMS) website ( www.cms.gov ), we obtained CMS quarterly payment amounts between January 1, 2005, and October 1, 2014, for alteplase, listed as alteplase recombinant, per mg. CMS payment amounts are the manufacturer’s average sales price+6% until April 2014, when it was lowered to +4.3%. Estimates for DRG base payments were calculated within the Medicare Provider and Analysis Review (MEDPAR) for fiscal years 2006 (DRG 559) and 2013 (MS DRGs 61, 62, and 63) as (DRG relative weights)×(standardized operating and capital amount). The consumer price index was also queried for all prescription drugs, urban areas, during the same study period as reference. Results—: The CMS payment amount for alteplase per milligram was $30.50 in January 2005 and $64.30 in October 2014. Trends in the CMS payment amounts for alteplase increased by 111% between 2005 and 2014. The consumer price index for all prescription drugs increased by 30.2% in the same time frame. The base payment for alteplase-treated stroke admissions was $11 173 in 2006 and $12 064 in 2013, an 8% increase. Conclusions—: We found a striking increase in the cost of alteplase over the last decade, with a 100 mg vial now with a CMS payment of ≈$6400, a >100% increase over 10 years. During the same time frame, the DRG base payment to hospitals increased by only 8%, and alteplase cost increased from 27% of the payment in 2006 to 53% in 2013. Researchers and stroke physicians should be aware of these changes in drug costs and their impact on cost-effectiveness analyses.
- 1 July 2017
- Published by Wolters Kluwer Health in Stroke
- Vol. 48 (7) , 2000-2002
Cost of Alteplase Has More Than Doubled Over the Past Decade
Background and Purpose—: Intravenous alteplase (tissue-type plasminogen activator) has been shown to be cost-effective because of savings in long-term disability. In October of 2005, an increased DRG payment to hospitals for alteplase-treated stroke patients was introduced. We sought to describe the trends in the cost of alteplase over time, in comparison to trends in hospital reimbursement in the United States. Methods—: Using publicly available information on the Centers for Medicare and Medicaid Services (CMS) website ( www.cms.gov ), we obtained CMS quarterly payment amounts between January 1, 2005, and October 1, 2014, for alteplase, listed as alteplase recombinant, per mg. CMS payment amounts are the manufacturer’s average sales price+6% until April 2014, when it was lowered to +4.3%. Estimates for DRG base payments were calculated within the Medicare Provider and Analysis Review (MEDPAR) for fiscal years 2006 (DRG 559) and 2013 (MS DRGs 61, 62, and 63) as (DRG relative weights)×(standardized operating and capital amount). The consumer price index was also queried for all prescription drugs, urban areas, during the same study period as reference. Results—: The CMS payment amount for alteplase per milligram was $30.50 in January 2005 and $64.30 in October 2014. Trends in the CMS payment amounts for alteplase increased by 111% between 2005 and 2014. The consumer price index for all prescription drugs increased by 30.2% in the same time frame. The base payment for alteplase-treated stroke admissions was $11 173 in 2006 and $12 064 in 2013, an 8% increase. Conclusions—: We found a striking increase in the cost of alteplase over the last decade, with a 100 mg vial now with a CMS payment of ≈$6400, a >100% increase over 10 years. During the same time frame, the DRG base payment to hospitals increased by only 8%, and alteplase cost increased from 27% of the payment in 2006 to 53% in 2013. Researchers and stroke physicians should be aware of these changes in drug costs and their impact on cost-effectiveness analyses.
- Open Access
- 25 September 2015
- Published by Springer Nature in BMC Neurology
- Vol. 15 (1) , 1-6
The impact of Magnetic Resonance Imaging (MRI) on ischemic stroke detection and incidence: minimal impact within a population-based study
There are several situations in which magnetic resonance imaging (MRI) might impact whether an cerebrovascular event is considered a new stroke. These include clinically non-focal events with positive imaging for acute cerebral infarction, and worsening of older symptoms without evidence of new infarction on MRI. We sought to investigate the impact of MRI on stroke detection and stroke incidence, by describing agreement between a strictly clinical definition of stroke and a definition based on physician opinion, including MRI imaging findings. All hospitalized strokes that occurred in five Ohio and Northern Kentucky counties (population 1.3 million) in the calendar year of 2005 were identified using ICD-9 discharge codes 430–436. The two definitions used were: “clinical case definition” which included sudden onset focal neurologic symptoms referable to a vascular territory for >24 h, compared to the “best clinical judgment of the physician definition”, which considers all relevant information, including neuroimaging findings. The 95 % confidence intervals (CI) for the incidence rates were calculated assuming a Poisson distribution. Rates were standardized to the 2000 U.S. population, adjusting for age, race, and sex, and included all age groups. There were 2403 ischemic stroke events in 2269 patients; 1556 (64 %) had MRI performed. Of the events, 2049 (83 %) were cases by both definitions, 185 (7.7 %) met the clinical case definition but were non-cases in the physician’s opinion and 169 (7.0 %) were non-cases by clinical definition but were cases in the physician’s opinion. There was no significant difference in the incidence rates of first-ever or total ischemic strokes generated by the two different definitions, or when only those with MRI imaging were included. We found that MRI findings do not appear to substantially change stroke incidence estimates, as the strictly clinical definition of stroke did not significantly differ from a definition that included imaging findings. Including MRI in the case definition “rules out” almost the same number of strokes as it “rules in”.
- 25 September 2015
- Published by Springer Nature in BMC Neurology
- Vol. 15 (1) , 1-6
Open AccessThe impact of Magnetic Resonance Imaging (MRI) on ischemic stroke detection and incidence: minimal impact within a population-based study
There are several situations in which magnetic resonance imaging (MRI) might impact whether an cerebrovascular event is considered a new stroke. These include clinically non-focal events with positive imaging for acute cerebral infarction, and worsening of older symptoms without evidence of new infarction on MRI. We sought to investigate the impact of MRI on stroke detection and stroke incidence, by describing agreement between a strictly clinical definition of stroke and a definition based on physician opinion, including MRI imaging findings. All hospitalized strokes that occurred in five Ohio and Northern Kentucky counties (population 1.3 million) in the calendar year of 2005 were identified using ICD-9 discharge codes 430–436. The two definitions used were: “clinical case definition” which included sudden onset focal neurologic symptoms referable to a vascular territory for >24 h, compared to the “best clinical judgment of the physician definition”, which considers all relevant information, including neuroimaging findings. The 95 % confidence intervals (CI) for the incidence rates were calculated assuming a Poisson distribution. Rates were standardized to the 2000 U.S. population, adjusting for age, race, and sex, and included all age groups. There were 2403 ischemic stroke events in 2269 patients; 1556 (64 %) had MRI performed. Of the events, 2049 (83 %) were cases by both definitions, 185 (7.7 %) met the clinical case definition but were non-cases in the physician’s opinion and 169 (7.0 %) were non-cases by clinical definition but were cases in the physician’s opinion. There was no significant difference in the incidence rates of first-ever or total ischemic strokes generated by the two different definitions, or when only those with MRI imaging were included. We found that MRI findings do not appear to substantially change stroke incidence estimates, as the strictly clinical definition of stroke did not significantly differ from a definition that included imaging findings. Including MRI in the case definition “rules out” almost the same number of strokes as it “rules in”.
- 1 June 2013
- Published by Wolters Kluwer Health in Stroke
- Vol. 44 (6_suppl_1) , S129-31
Temporal Trends in Acute Stroke Management
- 1 June 2013
- Published by Wolters Kluwer Health in Stroke
- Vol. 44 (6_suppl_1) , S129-31
Temporal Trends in Acute Stroke Management
- 1 April 2013
- Published by Wolters Kluwer Health in Stroke
- Vol. 44 (4) , 949-950
Understanding the Remarkable Decline in Stroke Mortality in Recent Decades
- 1 April 2013
- Published by Wolters Kluwer Health in Stroke
- Vol. 44 (4) , 949-950
Understanding the Remarkable Decline in Stroke Mortality in Recent Decades
- 23 August 2012
- Published by Springer Nature in Child's Nervous System
- Vol. 29 (1) , 99-103
Malignant MCA territory infarction in the pediatric population: subgroup analysis of the Greater Cincinnati/Northern Kentucky Stroke Study
Malignant middle cerebral artery (MCA) infarctions are thought to be rare in children. In a recent hospital-based study, only 1.3 % of pediatric ischemic strokes were malignant MCA infarctions. However, population-based rates have not been published. We performed subgroup analysis of a population-based study to determine the rate of malignant MCA infarctions in children.
- 23 August 2012
- Published by Springer Nature in Child's Nervous System
- Vol. 29 (1) , 99-103
Malignant MCA territory infarction in the pediatric population: subgroup analysis of the Greater Cincinnati/Northern Kentucky Stroke Study
Malignant middle cerebral artery (MCA) infarctions are thought to be rare in children. In a recent hospital-based study, only 1.3 % of pediatric ischemic strokes were malignant MCA infarctions. However, population-based rates have not been published. We performed subgroup analysis of a population-based study to determine the rate of malignant MCA infarctions in children.